The La Fe Health Research Institute of Valencia, in collaboration with the company Arthex Biotech, have organised the III Spanish Meeting on Oligonucleotide Therapeutics, SMOT III, at the Faculty of Pharmacy of the University of Valencia on October 26 and 27. The event brings together experts, the cutting edge in research and entrepreneurship, and investment companies to foster collaboration and promote advances in the field of therapeutic oligonucleotides (ONs).
These types of molecules are gaining great relevance in the search for therapies for diseases that lacked treatment. These are synthetic DNA or RNA molecules specifically directed at the target sequence responsible for the disease or some of its symptoms.
SMOT III aims to provide a platform to discuss and share success stories of outstanding companies and innovative projects in the field of not only oligonucleotides, but also the development of innovative medicines, medical devices and interesting biotechnological projects. During the event, which starts on Thursday, October 26 at 9:20 a.m., entrepreneurs will present their ideas and advances, offering a unique perspective on the future of the industry and the next generation of therapies.
In addition, emphasis will be placed on the keys to developing an entrepreneurial project from the academy and advice will be given to attract private and public investment. Finally, leading researchers and companies will share their latest discoveries, including new design strategies, drug synthesis and delivery technologies, as well as tools to facilitate these developments, and share promising results from preclinical and clinical studies.
This event has the support of the Department of Innovation, Universities, Sciences and Digital Society of the Valencian Government, the Oligonucleotide Therapeutics Society (OTS) and sponsoring companies (Asphalion, LGC Axolabs, Polypeptide, Wuxi TIDES, Sylentis and Deltalab-Biorad Laboratories, Hoffman Eitle, Abzu Aps, Arthex Biotech, Fisher Scientific), as well as the University Institute of Biotechnology and Biomedicine (BIOTECMED) of the University of Valencia.
The University of Valencia is researching a drug for limb-girdle muscular dystrophy (LGMDD2), which causes progressive atrophy
